Clinical trial
A Randomized, Parallel-Group Double-Blind, Biosimilar Trial to Compare Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of PB018 Versus Ocrevus® in Participants With Multiple Sclerosis (MS)
NCT07606521 is registered in ClinicalTrials.gov with Polpharma Biologics International AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Parallel-Group Double-Blind, Biosimilar Trial to Compare Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of PB018 Versus Ocrevus® in Participants With Multiple Sclerosis (MS)
- Lead sponsor
- Polpharma Biologics International AG
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- April 30, 2028
- Enrollment
- 222 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.